Incyte 2014 Annual Report
to Stockholders
Jakafi® (ruxolitinib)
Prescribing Information

is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs, primarily for oncology.

Incyte’s Emerging Development Pipeline Described in Eleven Abstracts at 2015 AACR Annual Meeting
Incyte to Establish European Headquarters in Geneva, Switzerland
Incyte Appoints Steven H. Stein, MD as Chief Medical Officer
Jakafi® (ruxolitinib)
Connecting to Access, Reimbursement, Education and Support
To learn more, click here